Please login to the form below

Not currently logged in

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

Merck and Co - US headquarters

Merck & Co has expanded its efforts to research new diabetes treatments, signing a new partnership with California-based biopharma Abide Therapeutics.

Worth $430m in upfront, funding and milestone payments, the deal covers three targets identified by Abide as potential targets for therapies in type 2 diabetes for which Merck will gain worldwide commercial rights.

These targets are part of a group of enzymes know as serine hydrolases, which Abide says have potential in the treatment of metabolic conditions, such as diabetes.

There are some 200 human serine hydrolases, but most are poorly categorised and the group has remained largely unexplored as drug targets.

Merck's large fee demonstrates some level of confidence in their potential in diabetes - an increasingly competitive market as levels increase across the world.

The unique enzyme-based method of treatment offered by Abide will also be attractive to Merck, with several diabetes products facing stricter regulation and tough approval processes due to increased concerns about their cardiovascular safety.

The deal comes just days after Merck announced it would collaborate with Pfizer on phase III diabetes compound ertugliflozin.

The sodium glucose co-transporter (SGLT2) inhibitor was originality developed by Pfizer and now a Merck subsidiary will work alongside it on in late development and helping to commercialise ertugliflozin if it is approved.

One of the key reason for the Pfizer deal is the potential to combine ertugliflozin with Merck's DPP-4 inhibitor Januvia (sitagliptin).

Merck also has a Januvia follow-up in development, with phase IIb data suggesting that MK-3102 could offer a similar level of effectiveness, but at a once-weekly rather than once-daily dosage.

3rd May 2013

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
5 ways that lockdowns and restrictions could be affecting our allergies
Over this last year, lockdowns and restrictions have led to changes in the day-to-day environments for people across the world. For Allergy Awareness week, we wanted to explore some of...